Gilead Sciences has agreed to acquire Arcellx in an all-cash transaction valued at $7.8 billion, or $115 per share, with an additional $5-per-share contingent value right contingent on future milestones. The transaction expands Gilead's oncology capabilities through the addition of anito-cel, a CAR T-cell therapy currently in development for multiple myeloma treatment, which has demonstrated promising results in clinical trials.
The acquisition marks a strategic investment in cell therapy innovation, a segment gaining prominence in cancer treatment protocols. By integrating Arcellx's pipeline and expertise, Gilead aims to strengthen its position in the competitive oncology market, where CAR T-cell therapies represent a rapidly evolving treatment modality. The contingent consideration structure ties additional payments to regulatory and commercial achievements, aligning financial outcomes with clinical and market success.
Arcellx shareholders responded positively to the announcement, with the company's stock trading near its 52-week highs following the news. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions and regulatory approvals.